Detalhe da pesquisa
1.
The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
Ann Hematol
; 102(9): 2529-2542, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37490114
2.
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Blood
; 136(26): 3041-3050, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367545
3.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Blood
; 135(5): 371-380, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826241
4.
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Ann Hematol
; 101(8): 1689-1701, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488900
5.
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Blood
; 134(19): 1608-1618, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31554635
6.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Blood
; 133(8): 840-851, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563875
7.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med
; 377(5): 454-464, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28644114
8.
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Blood
; 132(16): 1703-1713, 2018 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190321
9.
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Blood
; 140(3): 285-289, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507690
10.
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Br J Haematol
; 183(2): 235-241, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30378121
11.
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).
Haematologica
; 108(8): 2244-2248, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601981
12.
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Ann Hematol
; 96(6): 895-904, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331964
13.
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.
Blood
; 123(6): 914-20, 2014 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335498
14.
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
Blood
; 124(23): 3441-9, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25270908
15.
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Haematologica
; 101(7): 839-45, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27036160
16.
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
Ann Hematol
; 95(12): 1931-1942, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27696203
17.
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Br J Haematol
; 169(5): 694-700, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25818407
18.
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Blood
; 122(14): 2443-52, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23982172
19.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Blood
; 122(16): 2877-87, 2013 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23954893
20.
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Blood
; 122(1): 100-8, 2013 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704090